Initial Virological Response and Viral Mutation with Adefovir Dipivoxil Added to Ongoing Lamivudine Therapy in Lamivudine-Resistant Chronic Hepatitis B

Wu, Shuang; Fukai, Kenichi; Imazeki, Fumio; Arai, Makoto; Yonemitsu, Yutaka; Yokosuka, Osamu

doi:10.1007/s10620-010-1423-y

Cited by 9 publications

(14 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, ETV resulted in less ETVresistant mutations in NUC-naive Japanese patients than in previous reports with other drugs such as 3TC [5,18]. In conclusion, attention should be paid to patients with poor adherence as well as emerging ETV-resistant mutations in HBV during ETV-treatment.…”

Section: Discussioncontrasting

confidence: 45%

“…In conclusion, attention should be paid to patients with poor adherence as well as emerging ETV-resistant mutations in HBV during ETV-treatment. [5].…”

Section: Discussionmentioning

confidence: 99%

“…In Japan, the prevalence of HBV carriers is estimated at~1% of the population, but HBV is one of the major health issues because it leads to acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: Virological breakthrough is also dependent on adherence to medication

Kamezaki

Nakamoto

et al. 2011

Scandinavian Journal of Gastroenterology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 45%

“…In conclusion, attention should be paid to patients with poor adherence as well as emerging ETV-resistant mutations in HBV during ETV-treatment. [5].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: Virological breakthrough is also dependent on adherence to medication

Kamezaki

Nakamoto

et al. 2011

Scandinavian Journal of Gastroenterology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although ADV add-on LAM rescue therapy has shown acceptable antiviral efficacy in patients with LAM-resistant CHB [27,28], patients with a suboptimal response to this antiviral regimen have emerged [29,30]. However, this situation seems difficult to handle by changing or adding another antiviral agent, because the number of available potent NUCs with a high genetic barrier is significantly limited.…”

Section: Discussionmentioning

confidence: 99%

Partial Virological Response to Adefovir Add-On Lamivudine Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B

et al. 2013

View full text Add to dashboard Cite

Background/Aims: In patientswith lamivudine (LAM)-resistant chronic hepatitis B (CHB)receivingadefovir (ADV) add-on LAM therapy, insufficient viral suppression or the appearance of additional ADV resistance has remained unresolved. This study determined the partial virological response (PVR) criteria to predict a virological response (VR) at week 96 in these patients. Methods: 96 patients with LAM-resistant CHB (ADV add-on LAM therapy >2 years) were analyzed. For predicting VR at week 96, the area under the receiver operating characteristic curve values at different time points were compared to establish the optimal time point, and the maximal Youden index was calculated to determine the optimal cut-off hepatitis B virus (HBV) DNA level. Results: 50 (52.1%) patients achieved VR at 2 years after ADV add-on LAM therapy. The optimal PVR criteria were determined to be HBV DNA 500 IU/ml at week 48. 44 (45.8%) patients who met optimal PVR criteria showed a significantly higher risk for detectable HBV DNA levels at week 96 than those with a favorable VR (HBVDNA <500 IU/ml) at week 48. Conclusions: This study suggested optimal PVR criteria in patients with LAM-resistant CHB receiving ADV add-on LAM therapy. Modification of the antiviral agent regimen should be considered if the serum HBV DNA level exceeds 500 IU/ml at week 48.

show abstract

“…Apart from interferon, with the use of NUCs such as entecavir and tenofovir, it is always possible for resistant mutants to emerge [97][98][99][100][101] . Suzuki et al [101] reported that 51-year-old Japanese women with chronic hepatitis B and cirrhosis have virological breakthrough during combination therapy with tenofovir and entecavir against entecavir-resistant virus.…”

Section: Stoppage Of Entecavir or Tenofovirmentioning

confidence: 99%

Current and future directions for treating hepatitis B virus infection

Tawada

Yokosuka

2015

WJH

View full text Add to dashboard Cite

Hepatitis B virus (HBV) persistently infects approximately 350 million people, and approximately 600000 liverrelated deaths are observed per year worldwide. HBV infection is also one of the major risk factors for hepatocellular carcinoma (HCC). The persistence of serum hepatitis B e antigen (HBeAg) and high level of serum HBV DNA are thought to reflect a high HBV replication status in hepatocytes, causing cirrhosis, HCC and liver-related deaths. It has been reported that antiviral therapy, such as peginterferon and nucleos(t)ide analogues (NUCs), could suppress liver-related death by inhibiting the HBV DNA levels and inducing seroconversion from HBeAg to antibody to HBe antigen. Currently, peginterferon is widely used, but there are also several disadvantages in the use of peginterferon, such as various adverse events, the administration route and duration. It is difficult to predict the effects of treatment and interferon is contraindicated for the patients with advanced fibrosis of the liver and cirrhosis. With respect to NUCs, entecavir and tenofovir disoproxil fumarate are current the first-choice drugs. NUCs can be administered orally, and their anti-viral effects are stronger than that of peginterferon. However, because cessation of NUC administration leads to high levels of viral replication and causes severe hepatitis, they must be administered for a long time. On the other hand, the use of both interferon and NUCs cannot eliminate covalently closed circular DNA of HBV. In this review, we evaluate the natural course of chronic HBV infection and then provide an outline of these representative drugs, such as peginterferon, entecavir and tenofovir disoproxil fumarate.

show abstract

Initial Virological Response and Viral Mutation with Adefovir Dipivoxil Added to Ongoing Lamivudine Therapy in Lamivudine-Resistant Chronic Hepatitis B

Abstract: IVR is useful for predicting the antiviral efficacy of ADV and LAM combination therapy in LAM-resistant CHB.

Cited by 9 publications

References 40 publications

Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: Virological breakthrough is also dependent on adherence to medication

Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: Virological breakthrough is also dependent on adherence to medication

Partial Virological Response to Adefovir Add-On Lamivudine Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B

Current and future directions for treating hepatitis B virus infection

Contact Info

Product

Resources

About